Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

RCKT

Rocket Pharmaceuticals Inc

Sep 15 • 04:00PM ET

3.22

+0.06 1.90 %

Healthcare • Biotechnology • USA • NASD

Peers: SRPT CRSP NTLA QURE BLUE EDIT ALLO SGMO ADVM VYGR

| Held by: VTI IWM VXF IWN IBB SCHA VTWO FESM VHT IWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.50	Insider Own	8.62%	Shs Outstand	107.88M	Perf Week	-1.23%
Market Cap	347.44M	Forward P/E	-	EPS next Y	-1.21	Insider Trans	-0.08%	Shs Float	98.61M	Perf Month	6.27%
Enterprise Value	101.15M	PEG	-	EPS next Q	-0.48	Inst Own	84.80%	Short Float	15.71%	Perf Quarter	9.90%
Income	-257.30M	P/S	-	EPS this Y	25.25%	Inst Trans	-15.76%	Short Ratio	3.79	Perf Half Y	-63.24%
Sales	0.00M	P/B	0.98	EPS next Y	40.65%	ROA	-59.33%	Short Interest	15.49M	Perf YTD	-74.38%
Book/sh	3.28	P/C	1.28	EPS next 5Y	20.15%	ROE	-69.65%	52W High	22.01 -85.37%	Perf Year	-83.08%
Cash/sh	2.52	P/FCF	-	EPS past 3/5Y	-0.69% -11.60%	ROIC	-68.34%	52W Low	2.19 47.03%	Perf 3Y	-79.52%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	4.64% 6.89%	Perf 5Y	-86.03%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	10.36%	Oper. Margin	-	ATR (14)	0.21	Perf 10Y	-93.56%
Dividend Ex-Date	-	Quick Ratio	6.39	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	49.27	Recom	2.06
Dividend Gr. 3/5Y	- -	Current Ratio	6.39	EPS Q/Q	16.44%	SMA20	-2.90%	Beta	0.60	Target Price	7.86
Payout	-	Debt/Eq	0.07	Sales Q/Q	-	SMA50	1.83%	Rel Volume	0.56	Prev Close	3.16
Employees	299	LT Debt/Eq	0.06	Earnings	Aug 07 AMC	SMA200	-53.80%	Avg Volume	4.09M	Price	3.22
IPO	Feb 18, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.16% -	Trades		Volume	2,304,869	Change	1.90%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-25	Upgrade	BofA Securities	Neutral → Buy	$10
Jul-25-25	Downgrade	BofA Securities	Buy → Neutral	$4
May-30-25	Downgrade	Evercore ISI	Outperform → In-line	$5
May-28-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$7
May-28-25	Downgrade	Leerink Partners	Outperform → Market Perform	$8
May-28-25	Downgrade	JP Morgan	Overweight → Neutral
May-28-25	Downgrade	Jefferies	Buy → Hold	$2.50
May-28-25	Downgrade	Goldman	Neutral → Sell	$2
May-27-25	Downgrade	TD Cowen	Buy → Hold
May-27-25	Downgrade	Needham	Buy → Hold
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$50
Dec-30-24	Initiated	Wedbush	Outperform	$32
Dec-18-24	Initiated	Jefferies	Buy	$29
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Apr-02-24	Initiated	Goldman	Neutral	$39
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$65
Feb-01-23	Initiated	Morgan Stanley	Overweight	$45
Nov-08-22	Initiated	Canaccord Genuity	Buy	$53
Nov-01-22	Initiated	BTIG Research	Buy	$35
Jul-08-22	Initiated	Raymond James	Outperform	$22

Show Previous Ratings

Aug-28-25 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-21-25 11:13AM	RCKT Stock Rises as FDA Lifts Clinical Hold on Danon Disease Study (Zacks)
07:10AM	Rocket to relaunch rare disease trial after FDA approval (Clinical Trials Arena)
Aug-20-25 11:02AM	Gene Therapy Trial Can Restart After Patient Death, FDA Says. The Sector Remains Depressed. (Barrons.com) +28.87%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
07:00AM	Loading…
07:00AM	Rocket Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on the Pivotal Phase 2 Trial of RP-A501 for the Treatment of Danon Disease (Business Wire)
06:46AM	Rocket can resume gene therapy trial after FDA lifts hold (BioPharma Dive)
Aug-19-25 12:09AM	Jefferies Raises PT on Rocket Pharmaceuticals, Inc. (RCKT) to $3.00; Maintains 'Hold' Rating (Insider Monkey)
Aug-17-25 11:41PM	Rocket Pharmaceuticals Reorganizes, Cuts Workforce by 30% to Focus on AAV Cardiovascular Platform (Insider Monkey)
Aug-07-25 04:07PM	Rocket Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) -7.44%
04:00PM	Rocket Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire)
Aug-06-25 04:24PM	Did You Lose Money on Rocket Pharmaceuticals, Inc. (RCKT)? Levi & Korsinsky Urges Investors to Act Before August 11, 2025 (Newsfile)
Aug-05-25 08:45AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jul-30-25 04:37PM	Investors in Rocket Pharmaceuticals, Inc. (RCKT): Protect Your Rights - Contact Levi & Korsinsky Before August 11, 2025 (Newsfile)
01:14PM	Top FDA Official's Surprise Departure Means More Uncertainty for Biotech (Barrons.com)
08:45AM	Loading…
Jul-29-25 08:45AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jul-24-25 07:00AM	Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs (Business Wire)
06:55AM	Rocket lays off staff; Abivax capitalizes on immune drug data (BioPharma Dive)
Jul-18-25 11:28AM	RCKT Stock Up on FDA's RMAT Tag to Gene Therapy for Heart Failure (Zacks) -8.98%
Jul-17-25 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A601 Gene Therapy for PKP2-Arrhythmogenic Cardiomyopathy (Business Wire) +16.78%
Jul-15-25 08:58AM	Rocket Pharmaceuticals Receives FDA IND Clearance for BAG3-DCM Gene Therapy RP-A701 (Insider Monkey) -7.87%
Jul-10-25 09:55AM	Danon Disease Treatment Modality Market Analysis and Forecasts 2025-2035 \| Next-Gen Sequencing Speeds Up Danon Disease Diagnosis and Treatment Pathways (GlobeNewswire)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks) +5.71%
09:00AM	Investors in Rocket Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
07:25AM	Rocket Pharmaceuticals receives FDA clearance of RP-A701 (TipRanks)
Jun-30-25 07:00AM	Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy (Business Wire)
Jun-20-25 11:27AM	Gene Therapy Was the Biggest Idea in Biotech. Now It Has Lost Support on Wall Street. (Barrons.com)
09:00AM	Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKT (PR Newswire)
Jun-19-25 03:00AM	Gene Therapy Has Lost Support on Wall Street. There's Still Hope for Big Cures. (Barrons.com)
May-28-25 06:00PM	Leerink Partners Downgrades Rocket Pharmaceuticals (RCKT) to Market Perform on Danon Disease Blow (Insider Monkey) +6.44% +5.65%
01:20PM	Loading…
01:20PM	William Blair Reaffirms Outperform Rating on Rocket Pharma Despite Trial Setback (Insider Monkey)
11:09AM	RCKT Stock Tanks on Patient Death in Danon Disease Study (Zacks)
May-27-25 08:01PM	Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death (Insider Monkey) -62.84%
11:50AM	Top Stock Movers Now: Tesla, AutoZone, Newmont, and More (Investopedia)
11:35AM	Rocket Pharmaceuticals Stock Craters After Gene Therapy Patient Dies (Investopedia)
10:37AM	CoreWeave, Rocket Pharmaceuticals, SoundHound: Trending Tickers (Yahoo Finance Video)
07:00AM	Rocket Pharmaceuticals Provides Update on Phase 2 Clinical Trial of RP-A501 for Danon Disease (Business Wire)
May-15-25 03:15PM	Rocket Pharmaceuticals Presents Preliminary Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy at 28th Annual Meeting of the American Society of Gene and Cell Therapy (Business Wire) +11.07%
May-13-25 08:54AM	Is Rocket Pharmaceuticals (RCKT) the Best Low Priced Biotech Stock to Buy Now? (Insider Monkey) -5.50%
May-09-25 04:30PM	Rocket Pharmaceuticals Announces Late-Breaking Oral Presentation of Data from Phase 1 Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy Accepted at 28th Annual Meeting of the American Society of Gene and Cell Therapy (Business Wire)
10:41AM	RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
May-08-25 04:01PM	Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Progress (Business Wire) +5.07%
Apr-16-25 11:59AM	Big banks report Q1 beats, China stops taking Boeing deliveries: Morning Buzz (TipRanks) -5.82%
Apr-10-25 11:16AM	Rocket Pharma Out Of Orbit, But Ready For Relaunch (Seeking Alpha) -8.52%
Apr-09-25 10:55AM	Rocket Pharmaceuticals (RCKT): Among Stocks Under $10 that Will Triple (Insider Monkey) +12.73%
Apr-03-25 07:00AM	Rocket Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference (Business Wire) -11.75%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -12.89%
Mar-26-25 10:40AM	Is Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) the Best US Stock Under $10 to Buy Right Now? (InsiderMonkey) -5.88%
Feb-27-25 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress (Business Wire)
Jan-02-25 04:00PM	Rocket Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-24 08:05AM	Wedbush starts Rocket Pharmaceuticals with Outperform into inflection year (TipRanks)
Dec-18-24 02:16PM	Rocket Pharmaceuticals Stock Soars as Jefferies Initiates Coverage at 'Buy' (Investopedia)
Dec-11-24 07:00AM	Rocket Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (Business Wire)
Dec-10-24 04:01PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-26-24 07:00AM	Rocket Pharmaceuticals to Participate in the 7th Annual Evercore HealthCONx Conference (Business Wire)
Nov-18-24 11:00AM	Rocket Pharmaceuticals Announces New England Journal of Medicine Publication of Phase 1 RP-A501 Long-Term Data and Presents at Late-Breaking Scientific Sessions at 2024 American Heart Association Conference (Business Wire)
Nov-12-24 04:01PM	Rocket Pharmaceuticals to Present Updated Data from the Phase 1 Clinical Trial of RP-A501 for Danon Disease at the American Heart Associations 2024 Late-Breaking Science Sessions (Business Wire)
Nov-08-24 07:00AM	Rocket Pharmaceuticals to Participate in the UBS Global Healthcare Conference (Business Wire)
Nov-07-24 04:01PM	Rocket Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Sep-17-24 07:00AM	Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease (Business Wire) +13.54%
Sep-10-24 07:00AM	Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors (Business Wire)
Aug-27-24 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-25-24 09:06AM	Morgan Stanley Predicts up to 220% Jump for These 2 Strong Buy Stocks (TipRanks)
Aug-05-24 09:55PM	RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024 (InvestorPlace)
04:01PM	Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Jun-28-24 12:30PM	FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment (Investopedia)
07:27AM	Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI (marnetegragene autotemcel; marne-cel) (Business Wire)
Jun-05-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report? (Zacks)
May-29-24 07:00AM	Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (Business Wire)
May-10-24 06:00AM	Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Business Wire)
May-07-24 11:26AM	Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil (Zacks)
May-06-24 09:55PM	RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Apr-30-24 12:00PM	Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why (Zacks)
Apr-24-24 11:33AM	Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
07:39AM	Should You Hold Immunovant (IMVT)? (Insider Monkey)
Apr-03-24 11:32AM	EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia (Zacks)
Apr-02-24 06:00AM	Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia (Business Wire)
Mar-27-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report? (Zacks)
Mar-26-24 04:01PM	Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team (Business Wire)
Feb-27-24 12:20PM	Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4 (Zacks)
Feb-26-24 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress (Business Wire)
Feb-13-24 07:00AM	Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire)
Jan-22-24 03:39AM	Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey) +5.61%
Jan-04-24 11:55AM	Amazon and Nvidia Stock Have a Lot More Growth Ahead, This Manager Says (Barrons.com)
Jan-02-24 04:01PM	Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-23 07:00AM	Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors (Business Wire)
Nov-23-23 12:16PM	Billionaire Lee Ainslies Top 10 Stock Picks (Insider Monkey)
Nov-15-23 11:17AM	Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates (Zacks)
Nov-09-23 09:55AM	Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High? (Zacks) -7.15%
Nov-06-23 04:15PM	Rocket Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -5.00%
04:04PM	Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
Nov-05-23 07:30AM	With This Rally, Rocket Just Might Take Off (TheStreet.com)
Nov-02-23 06:26PM	Rocket Pharmaceuticals Stock Sees Improved Price Strength (Investor's Business Daily) +9.21%
Oct-27-23 02:49PM	Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher (Investor's Business Daily)
Oct-20-23 03:18AM	Should You Hold Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
Oct-19-23 07:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Oct-02-23 07:00AM	Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire) -5.08%
Sep-26-23 04:01PM	Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference (Business Wire)
Sep-23-23 09:45AM	Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals (Motley Fool)

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bjork Elisabeth	Director	Aug 27 '25	Buy	3.41	10,000	34,100	40,000	Aug 27 08:54 PM
Militello John	See Remarks	Aug 18 '25	Sale	3.06	699	2,142	56,285	Aug 20 05:00 PM
Militello John	See Remarks	Aug 19 '25	Sale	3.00	361	1,082	55,924	Aug 20 05:00 PM
Schwartz Jonathan David	See Remarks	Aug 18 '25	Sale	3.06	1,680	5,149	222,414	Aug 20 05:00 PM
Schwartz Jonathan David	See Remarks	Aug 19 '25	Sale	3.00	805	2,412	221,609	Aug 20 05:00 PM
Wilson Martin	General Counsel	Aug 18 '25	Sale	3.06	1,004	3,077	136,050	Aug 20 05:00 PM
Wilson Martin	General Counsel	Aug 19 '25	Sale	3.00	588	1,762	135,462	Aug 20 05:00 PM
Wilson Martin	Officer	Aug 19 '25	Proposed Sale	3.00	588	1,762		Aug 19 03:33 PM
Schwartz Jonathan David	Officer	Aug 19 '25	Proposed Sale	3.00	805	2,412		Aug 19 03:28 PM
Militello John	Officer	Aug 19 '25	Proposed Sale	3.00	361	1,082		Aug 19 03:28 PM
Schwartz Jonathan David	See Remarks	Aug 14 '25	Sale	3.02	11,161	33,695	224,094	Aug 18 04:35 PM
Militello John	See Remarks	Aug 14 '25	Sale	3.02	7,043	21,263	56,984	Aug 18 04:35 PM
Wilson Martin	General Counsel	Aug 14 '25	Sale	3.02	12,109	36,557	137,054	Aug 18 04:35 PM
Wilson Martin	Officer	Aug 18 '25	Proposed Sale	3.07	1,004	3,077		Aug 18 03:24 PM
Militello John	Officer	Aug 18 '25	Proposed Sale	3.07	699	2,143		Aug 18 03:10 PM
Schwartz Jonathan David	Officer	Aug 18 '25	Proposed Sale	3.07	1,680	5,150		Aug 18 03:10 PM
Militello John	Officer	Aug 14 '25	Proposed Sale	3.02	7,043	21,261		Aug 14 05:55 PM
Wilson Martin	Officer	Aug 14 '25	Proposed Sale	3.02	12,109	36,553		Aug 14 05:47 PM
Schwartz Jonathan David	Officer	Aug 14 '25	Proposed Sale	3.02	11,161	33,692		Aug 14 05:44 PM
Ondrey Aaron	Chief Financial Officer	Jul 03 '25	Sale	2.88	1,477	4,257	128,173	Jul 08 04:05 PM
Ondrey Aaron	Officer	Jul 03 '25	Proposed Sale	2.88	1,477	4,256		Jul 03 03:17 PM
Militello John	See Remarks	May 20 '25	Sale	6.45	357	2,301	64,027	May 22 04:05 PM
Schwartz Jonathan David	See Remarks	May 20 '25	Sale	6.45	801	5,163	235,255	May 22 04:05 PM
Patel Kinnari	See Remarks	May 20 '25	Sale	6.45	767	4,944	441,927	May 22 04:05 PM
Shah Gaurav	CEO	May 20 '25	Sale	6.45	2,253	14,523	786,806	May 22 04:05 PM
Wilson Martin	General Counsel	May 20 '25	Sale	6.45	587	3,784	149,163	May 22 04:05 PM
Militello John	See Remarks	May 16 '25	Sale	6.53	655	4,276	64,384	May 20 04:05 PM
Patel Kinnari	See Remarks	May 16 '25	Sale	6.53	1,409	9,198	442,694	May 20 04:05 PM
Schwartz Jonathan David	See Remarks	May 16 '25	Sale	6.53	1,582	10,327	236,056	May 20 04:05 PM
Shah Gaurav	CEO	May 16 '25	Sale	6.53	3,621	23,638	789,059	May 20 04:05 PM
Wilson Martin	General Counsel	May 16 '25	Sale	6.53	946	6,175	149,750	May 20 04:05 PM
Wilson Martin	Officer	May 20 '25	Proposed Sale	6.45	587	3,784		May 20 03:29 PM
Militello John	Officer	May 20 '25	Proposed Sale	6.45	357	2,301		May 20 03:21 PM
Schwartz Jonathan David	Officer	May 20 '25	Proposed Sale	6.45	801	5,163		May 20 03:17 PM
Shah Gaurav	Officer	May 20 '25	Proposed Sale	6.45	2,253	14,523		May 20 03:15 PM
Patel Kinnari	Officer	May 20 '25	Proposed Sale	6.45	767	4,944		May 20 03:13 PM
Schwartz Jonathan David	Officer	May 16 '25	Proposed Sale	6.53	1,582	10,327		May 16 04:13 PM
Shah Gaurav	Officer	May 16 '25	Proposed Sale	6.53	3,621	23,636		May 16 04:09 PM
Wilson Martin	Officer	May 16 '25	Proposed Sale	6.53	946	6,175		May 16 04:07 PM
Militello John	Officer	May 16 '25	Proposed Sale	6.53	655	4,276		May 16 03:32 PM
Patel Kinnari	Officer	May 16 '25	Proposed Sale	6.53	1,409	9,197		May 16 03:18 PM
Militello John	See Remarks	Apr 22 '25	Sale	7.16	718	5,139	65,039	Apr 24 04:06 PM
Militello John	Officer	Apr 22 '25	Proposed Sale	7.16	718	5,140		Apr 22 03:17 PM
Shah Gaurav	CEO	Apr 10 '25	Buy	5.08	20,000	101,600	792,680	Apr 14 06:57 PM
Patel Kinnari	See Remarks	Apr 09 '25	Buy	4.70	21,099	99,165	26,774	Apr 10 04:07 PM
White Mark Andrew	Former Officer	Apr 09 '25	Proposed Sale	4.67	3,382	15,777		Apr 09 03:26 PM
Ondrey Aaron	Chief Financial Officer	Apr 04 '25	Sale	5.29	7,489	39,647	129,650	Apr 08 04:06 PM
Ondrey Aaron	Officer	Apr 04 '25	Proposed Sale	5.29	7,489	39,647		Apr 04 03:25 PM
Schwartz Jonathan David	See Remarks	Feb 25 '25	Sale	10.58	6,532	69,109	237,638	Feb 27 04:01 PM
Schwartz Jonathan David	See Remarks	Nov 21 '24	Sale	13.05	3,097	40,416	163,852	Feb 27 04:01 PM
Patel Kinnari	See Remarks	Feb 21 '25	Sale	10.58	6,078	64,305	444,103	Feb 25 04:01 PM
Wilson Martin	General Counsel	Feb 21 '25	Sale	10.58	3,222	34,089	150,696	Feb 25 04:01 PM
Militello John	See Remarks	Feb 21 '25	Sale	10.58	2,737	28,957	65,757	Feb 25 04:01 PM
Shah Gaurav	CEO	Feb 21 '25	Sale	10.58	16,303	172,486	772,680	Feb 25 04:01 PM
Schwartz Jonathan David	Officer	Feb 25 '25	Proposed Sale	10.58	6,532	69,117		Feb 25 12:56 PM
Patel Kinnari	Officer	Feb 21 '25	Proposed Sale	10.58	6,078	64,313		Feb 21 04:29 PM
White Mark Andrew	Former Officer	Feb 21 '25	Proposed Sale	10.58	1,222	12,930		Feb 21 04:15 PM
Wilson Martin	Officer	Feb 21 '25	Proposed Sale	10.58	3,222	34,093		Feb 21 04:11 PM
Shah Gaurav	Officer	Feb 21 '25	Proposed Sale	10.58	16,303	172,507		Feb 21 04:11 PM
Militello John	Officer	Feb 21 '25	Proposed Sale	10.58	2,737	28,961		Feb 21 04:09 PM
White Mark Andrew	Former Officer	Jan 31 '25	Proposed Sale	10.96	2,824	30,943		Jan 31 03:15 PM
Militello John	See Remarks	Jan 23 '25	Sale	10.38	896	9,300	48,414	Jan 27 04:16 PM
Militello John	Officer	Jan 23 '25	Proposed Sale	10.38	896	9,301		Jan 23 03:33 PM
Militello John	See Remarks	Nov 21 '24	Sale	13.05	1,224	15,978	49,310	Nov 25 04:05 PM
Patel Kinnari	See Remarks	Nov 21 '24	Sale	13.05	4,588	59,892	392,395	Nov 25 04:05 PM
Shah Gaurav	CEO	Nov 21 '24	Sale	13.05	11,091	144,782	707,328	Nov 25 04:05 PM
Wilson Martin	General Counsel	Nov 21 '24	Sale	13.05	1,175	15,338	63,560	Nov 25 04:05 PM
Patel Kinnari	Officer	Nov 21 '24	Proposed Sale	13.05	4,588	59,892		Nov 21 04:26 PM
Militello John	Officer	Nov 21 '24	Proposed Sale	13.05	1,224	15,978		Nov 21 04:06 PM
Wilson Martin	Officer	Nov 21 '24	Proposed Sale	13.05	1,175	15,338		Nov 21 03:58 PM
Shah Gaurav	Officer	Nov 21 '24	Proposed Sale	13.05	11,091	144,782		Nov 21 03:27 PM
White Mark Andrew	See Remarks	Oct 31 '24	Sale	16.62	3,080	51,205	69,140	Nov 04 04:06 PM
Militello John	See Remarks	Oct 31 '24	Sale	16.62	917	15,245	50,534	Nov 04 04:05 PM
Militello John	Officer	Oct 31 '24	Proposed Sale	16.62	917	15,245		Oct 31 03:34 PM
White Mark Andrew	Officer	Oct 31 '24	Proposed Sale	16.62	3,080	51,205		Oct 31 03:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RCKT

Rocket Pharmaceuticals Inc

Upgrade your FINVIZ experience